Ubs Group Ag Reata Pharmaceuticals Inc Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
BUY
$79.22 - $105.37 $1.69 Million - $2.24 Million
21,283 Added 119.94%
39,027 $3.98 Million
Q1 2023

May 12, 2023
BUY
$30.85 - $93.17 $470,740 - $1.42 Million
15,259 Added 614.04%
17,744 $1.61 Million
Q4 2022

Feb 08, 2023
SELL
$22.15 - $42.11 $28,196 - $53,606
-1,273 Reduced 33.87%
2,485 $94,000
Q3 2022

Nov 10, 2022
BUY
$19.41 - $36.49 $23,292 - $43,788
1,200 Added 46.91%
3,758 $94,000
Q2 2022

Aug 10, 2022
BUY
$20.71 - $36.5 $15,718 - $27,703
759 Added 42.19%
2,558 $78,000
Q1 2022

May 16, 2022
SELL
$24.12 - $39.6 $42,427 - $69,656
-1,759 Reduced 49.44%
1,799 $59,000
Q4 2021

Feb 14, 2022
SELL
$25.61 - $110.96 $66,944 - $290,049
-2,614 Reduced 42.35%
3,558 $93,000
Q3 2021

Nov 15, 2021
SELL
$100.0 - $143.02 $120,700 - $172,625
-1,207 Reduced 16.36%
6,172 $621,000
Q2 2021

Aug 13, 2021
BUY
$78.27 - $151.29 $68,486 - $132,378
875 Added 13.45%
7,379 $1.04 Million
Q1 2021

May 12, 2021
SELL
$94.25 - $132.81 $879,635 - $1.24 Million
-9,333 Reduced 58.93%
6,504 $648,000
Q4 2020

Feb 11, 2021
SELL
$102.03 - $184.62 $2.4 Million - $4.34 Million
-23,506 Reduced 59.75%
15,837 $1.96 Million
Q3 2020

Nov 12, 2020
BUY
$93.53 - $163.34 $2.63 Million - $4.59 Million
28,122 Added 250.62%
39,343 $3.83 Million
Q2 2020

Jul 31, 2020
BUY
$126.3 - $176.56 $1.02 Million - $1.42 Million
8,060 Added 254.98%
11,221 $1.75 Million
Q1 2020

May 01, 2020
SELL
$124.16 - $247.74 $1.54 Million - $3.07 Million
-12,375 Reduced 79.65%
3,161 $456,000
Q4 2019

Feb 14, 2020
BUY
$74.57 - $217.92 $714,455 - $2.09 Million
9,581 Added 160.89%
15,536 $3.18 Million
Q3 2019

Nov 14, 2019
SELL
$71.26 - $95.75 $55,796 - $74,972
-783 Reduced 11.62%
5,955 $479,000
Q2 2019

Aug 14, 2019
SELL
$77.72 - $94.35 $1.67 Million - $2.03 Million
-21,483 Reduced 76.12%
6,738 $636,000
Q1 2019

May 14, 2019
BUY
$51.9 - $101.79 $38,302 - $75,121
738 Added 2.69%
28,221 $2.41 Million
Q4 2018

Feb 14, 2019
BUY
$48.76 - $76.44 $46,760 - $73,305
959 Added 3.62%
27,483 $1.54 Million
Q3 2018

Nov 14, 2018
SELL
$35.64 - $92.06 $303,688 - $784,443
-8,521 Reduced 24.31%
26,524 $2.17 Million
Q2 2018

Aug 14, 2018
BUY
$19.94 - $40.96 $301,333 - $618,987
15,112 Added 75.81%
35,045 $1.23 Million
Q1 2018

May 15, 2018
BUY
$20.0 - $30.19 $329,160 - $496,867
16,458 Added 473.61%
19,933 $409,000
Q4 2017

Feb 14, 2018
BUY
$22.39 - $33.27 $24,852 - $36,929
1,110 Added 46.93%
3,475 $99,000
Q3 2017

Nov 14, 2017
SELL
$26.29 - $31.88 $25,422 - $30,827
-967 Reduced 29.02%
2,365 $73,000
Q2 2017

Aug 14, 2017
BUY
N/A
2,109 Added 172.44%
3,332 $105,000
Q1 2017

Nov 14, 2017
BUY
N/A
1,223
1,223 $27,000

Others Institutions Holding RETA

# of Institutions
5
Shares Held
62.7K
Call Options Held
0
Put Options Held
0
View Full List

About REATA PHARMACEUTICALS INC

RETA Quotes by TradingView
  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email